Stammzell-ähnliche Eigenschaften von AR-V7 exprimierenden Prostatakarzinomzellen

Autor: Santer, F., Handle, F., Cronauer, M., Furlan, T.

Publikováno v: 46. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie; 20200514-20200516; Nürnberg; DOC20urobay005 /20200730/

Die endokrinen Therapieoptionen für das fortgeschrittene und kastrationsresistente Prostatakarzinom sind aktuell auf Substanzen beschränkt, welche die Liganden-Bindungsdomäne (LBD) des Androgenrezeptors (AR) entweder direkt (z.B. Enzalutamid) oder

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd9ca6707884a5632c3d9c3273662ba1
http://nbn-resolving.de/urn:nbn:de:0183-20urobay0052

Bedeutung der Androgenrezeptor-Spleißvariante AR-V7 für Prognose und Therapie des fortgeschrittenen Prostatakarzinoms. (German)

Autor: Thelen, P., Taubert, H., Duensing, S., Kristiansen, G., Merseburger, A. S., Cronauer, M. V.

Publikováno v: Aktuelle Urologie; 2020, Vol. 51 Issue 6, p582-592, 11p

Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression.

Autor: Cronauer, M. V.^1,2, Ince, Y.³, Engers, R.⁴, Rinnab, L.⁵, Weidemann, W.², Suschek, C. V.⁶, Burchardt, M.¹, Kleinert, H.⁷, Wiedenmann, J.², Sies, H.³, Ackermann, R.¹, Kröncke, K.-D.³ kroencke@uni-duesseldorf.de

Publikováno v: Oncogene. 3/22/2007, Vol. 26 Issue 13, p1875-1884. 10p. 1 Diagram, 5 Graphs.

Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells.

Autor: Cronauer, M V, Nessler-Menardi, C, Klocker, H, Maly, K, Hobisch, A, Bartsch, G, Culig, Z

Publikováno v: British Journal of Cancer. 1/1/2000, Vol. 82 Issue 1, p39. 7p.

Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2.

Autor: Chen L; Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany.; Department of Gastroenterology and Hepatology, Zhongda Hospital, Southeast University, Nanjing, China., Liu Y; Department of Gastroenterology and Hepatology, Zhongda Hospital, Southeast University, Nanjing, China., Becher A; Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany., Diepold K; Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany., Schmid E; Department of Pediatric Surgery and Pediatric Urology, University of Tübingen, Tübingen, Germany., Fehn A; Department of Otorhinolaryngology, University Hospital Ulm, Ulm, Germany., Brunner C; Department of Otorhinolaryngology, University Hospital Ulm, Ulm, Germany., Rouhi A; Terry Fox Laboratory, Vancouver, BC, Canada., Chiosis G; Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Institute, New York, NY, USA., Cronauer M; Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany., Seufferlein T; Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany., Azoitei N; Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany.

Publikováno v: Carcinogenesis [Carcinogenesis] 2020 Oct 15; Vol. 41 (10), pp. 1421-1431.